| Lisa Semmler, LMFT | |
|
3350 W Americana Ter Ste 360a, Boise, ID 83706-2521 | |
| (208) 866-2120 | |
| (208) 593-3266 |
| Full Name | Lisa Semmler |
|---|---|
| Gender | Female |
| Speciality | Counselor |
| Location | 3350 W Americana Ter Ste 360a, Boise, Idaho |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1144777087 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 101YM0800X | Counselor - Mental Health | (* (Not Available)) | Secondary |
| 101Y00000X | Counselor | LMFT-7805 (Idaho) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Lisa Semmler, LMFT 3350 W Americana Ter Ste 360a, Boise, ID 83706-2521 Ph: (208) 866-2120 | Lisa Semmler, LMFT 3350 W Americana Ter Ste 360a, Boise, ID 83706-2521 Ph: (208) 866-2120 |
News Archive
In community-based radiology practice, mammography screening with 3D digital breast tomosynthesis (DBT) yielded lower recall rates, an increased overall cancer detection rate, and an increased detection rate for invasive cancer compared with 2D digital mammography (DM).
Peering into the DNA of tiny yeast, researchers at the Moores Cancer Center at the University of California, San Diego and the San Diego Branch of the Ludwig Institute for Cancer Research have pinpointed a large number of genes that can prevent a type of genetic rearrangement that may lead to cancer and other diseases.
A study published today by an interdisciplinary collaboration, directed by Denis Engemann from Inria, demonstrates that machine learning from large population cohorts can yield "proxy measures" for brain-related health issues without the need for a specialist's assessment.
Bayer HealthCare announced today that the New Drug Application for its oral investigational compound riociguat has been accepted for filing and granted priority review by the U.S. Food and Drug Administration for the treatment of inoperable chronic thromboembolic pulmonary hypertension or with persistent or recurrent CTEPH after pulmonary endarterectomy and pulmonary arterial hypertension.
In a new study led by researchers at Yale Cancer Center, the drug enfortumab vedotin (EV) significantly prolonged survival as compared with standard chemotherapy in patients with locally advanced or metastatic urothelial carcinoma or bladder cancer, who had previously received platinum-based treatment and a PD-1–PD-L1 inhibitor.
› Verified 8 days ago
Roxanne L Pickerel, M.S., LCPC Counselor Medicare: Not Enrolled in Medicare Practice Location: 203 W Fort St, Boise, ID 83702 Phone: 208-841-8109 Fax: 208-203-1879 | |
Mrs. Mary Claire Fery, LPC Counselor Medicare: Not Enrolled in Medicare Practice Location: 410 S Orchard St Ste 128, Boise, ID 83705 Phone: 208-918-1283 | |
Rachel Marie Piazza Voight, Counselor Medicare: Not Enrolled in Medicare Practice Location: 1075 E Park Blvd, Boise, ID 83712 Phone: 208-381-5970 | |
Ms. Terri Turpin, LCPC Counselor Medicare: Not Enrolled in Medicare Practice Location: 1408 W Hays St, Boise, ID 83702 Phone: 208-429-5730 Fax: 208-336-7125 | |
Mr. Charles Edward Vollet, LCSW Counselor Medicare: Not Enrolled in Medicare Practice Location: 1510 Robert Street, Suite 101, Boise, ID 83705 Phone: 208-344-0844 Fax: 208-344-0592 | |
Debra Lynne Gallagher, LPC Counselor Medicare: Not Enrolled in Medicare Practice Location: 1111 S Orchard St Ste 290, Boise, ID 83705 Phone: 208-343-2770 | |
Caitlin Goicoechea, Counselor Medicare: Not Enrolled in Medicare Practice Location: 8950 W Emerald St Ste 178, Boise, ID 83704 Phone: 208-376-7083 |